Form 4: Cidara Therapeutics CEO Acquires Shares in Recent Transaction

Cidara Therapeutics' CEO, Jeffrey Stein, recently purchased 8,000 shares of common stock at an average price of $13.21 per share.

Summary

• On June 7, 2024, Jeffrey Stein, the President & CEO and a Director of Cidara Therapeutics, Inc., acquired 8,000 shares of common stock at a weighted average price of $13.21.
• The shares were purchased in multiple transactions with prices ranging from $13.05 to $13.29.
• Following the reported transaction, Stein beneficially owns 57,884 shares directly, 24,580 shares indirectly through a trust, and 2,100 shares indirectly through his son.
• The number of securities reported have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
• 200 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the size of the purchase is relatively small. The reverse stock split earlier in the year could indicate previous financial difficulties.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
• The CEO's purchase of shares demonstrates confidence in the company's future.

Industry Context

Insider buying is often viewed as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the size of the purchase relative to the executive's overall holdings and the company's market capitalization.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates